Global Krabbe Disease Treatment Market 2018-2022
About Krabbe Disease Treatment
Krabbe disease is a rare inherited genetic disorder that affects the nervous system. It is usually caused by the deficiency of the galactosylceramidase (GLC) enzyme. The disease is inherited in an autosomal recessive pattern.
Technavio’s analysts forecast the global krabbe disease treatment market to grow at a CAGR of 7.24% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global krabbe disease treatment market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Krabbe Disease Treatment Market 2018-2022
Technavio recognizes the following companies as the key players in the global krabbe disease treatment market: GlaxoSmithKline, Johnson & Johnson, and Novartis.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is emergence of pharmacological chaperone therapy. More than two-fifth known cases of Krabbe disease are due to missense mutation in the GLC enzyme. Such mutations result in the disruption of enzyme folding and ultimately stops the GLC from reaching its site of action in enough amounts in the lysosome.”
According to the report, one driver in the market is special drug designation. An important factor that is expected to drive market growth is the assignment of special drug designations to drugs and biologics that are intended for the safe and effective treatment of Krabbe disease. The priority review program for facilitating fast drug approvals is offered by the Food and Drug Administration (FDA).
Further, the report states that one challenge in the market is limited patient pool for clinical trials. The prevalence rate of orphan diseases such as Krabbe is very low. Therefore, the percentage of population affected by such diseases is also low in comparison with other disorders. This, in turn, restricts the number of patients available for clinical trial evaluation of drugs under development for the treatment of orphan diseases.
GlaxoSmithKline, Johnson & Johnson, and Novartis.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook